Physician profile
Robert E Hawver
NPI 1295900132
$13,624.27
in general payments reported to CMS, 2019-2025
32 companies · $4,253 in 2025
The $4,253 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $426 · 2022: $2,313 · 2023: $3,156 · 2024: $3,477 · 2025: $4,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,736.24 |
| Education | $148.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,163.79 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,849.77 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Mallinckrodt Hospital Products INC. | $1,236.05 | 2021-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $859.64 | 2021-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $816.19 | 2021-2025 | Ofev, Spiriva, Jascayd |
| United Therapeutics Corporation | $776.01 | 2021-2025 | Tyvaso, Tyvaso |
| Actelion Pharmaceuticals US, INC. | $736.40 | 2022-2025 | Opsumit, Uptravi |
| Mylan Specialty L.P. | $718.29 | 2021-2024 | Yupelri |
| Genzyme Corporation | $701.04 | 2021-2025 | |
| Insmed, INC. | $527.79 | 2022-2025 | Arikayce, Brinsupri |
| Baxter Healthcare | $470.42 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Ani Pharmaceuticals, INC. | $386.78 | 2023-2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $330.99 | 2022-2025 | Glassia |
| Verona Pharma, INC. | $296.96 | 2025 | Ohtuvayre |
| Amgen INC. | $285.11 | 2022-2025 | Tezspire |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $264.07 | 2025 | Yupelri |
| Grifols USA, LLC | $258.60 | 2022-2025 | Prolastin-C Liquid |
| Inogen, INC. | $191.67 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Merck Sharp & Dohme LLC | $184.66 | 2023-2025 | Winrevair |
| Novartis Pharmaceuticals Corporation | $124.52 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.13 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $50.76 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $45.05 | 2022 | |
| Pfizer INC. | $38.50 | 2022-2023 | |
| Nabriva Therapeutics, Plc | $37.90 | 2021-2022 | |
| Optinose US, INC. | $34.34 | 2024-2025 | |
| Sanofi Pasteur INC. | $30.56 | 2025 | |
| Pulmonx Corporation | $24.75 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Advanced Respiratory, INC | $20.34 | 2021 | |
| Inspire Medical Systems, INC. | $18.45 | 2025 | Inspire |
| Phadia US INC. | $16.60 | 2023 | Immunocap |
| Vapotherm INC | $13.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hawver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.